The mood spectrum and hypothalamic-pituitary-thyroid axis

Primary Psychiatry

Volumn 11, Issue 10, 2004, Pages 42-47

  Pfennig, Andrea ^a   Frye, Mark A ^b,c   Köberle, Ursula ^a   Bauer, Michael ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CARBAMAZEPINE; LIOTHYRONINE; LITHIUM; NEUROTRANSMITTER; SEROTONIN UPTAKE INHIBITOR; THYROID HORMONE; THYROXINE; TRICYCLIC ANTIDEPRESSANT AGENT;

BIPOLAR DISORDER; BRAIN METABOLISM; CLINICAL FEATURE; COGNITION; DEPRESSION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOCRINE SYSTEM; GABAERGIC SYSTEM; HUMAN; HYPERTHYROIDISM; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; HYPOTHYROIDISM; LIOTHYRONINE BLOOD LEVEL; MAINTENANCE THERAPY; MANIA; MOOD; MOOD DISORDER; NEUROIMAGING; NEUROTRANSMISSION; OUTCOMES RESEARCH; PATHOPHYSIOLOGY; PHOTOTHERAPY; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; RAPID CYCLING BIPOLAR DISORDER; RECURRENT DISEASE; REVIEW; SEROTONINERGIC SYSTEM; SLEEP DEPRIVATION; THYROID DISEASE; THYROID HORMONE BLOOD LEVEL; THYROXINE BLOOD LEVEL; TRANSCRANIAL MAGNETIC STIMULATION;

EID: 8444248307     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (89)

1. Parry CH. Collections From the Unpublished Writings of the Late C.H. Parry. Vol 2. London, UK: Underwoods; 1825.
2. Graves RJ. Newly observed affection of the thyroid gland in females. Lond Med Surg J. 1835;7:516-517.
3. Clinical Society of London. Report on myxedema. Trans Clin Soc Lond. 1888;(suppl):18-21.
4. Treadway CR, Prange AJ Jr, Doehne EF, Edens CJ, Whybrow PC. Myxedema psychosis: clinical and biochemical changes during recovery. J Psychiatr Res. 1967;5(4):289-296.
5. Asher R. Mysoedematous madness. Br Med J. 1949;22:555-562.
6. Prange AJ Jr, Wilson IC, Rabon AM, Lipton MA. Enhancement of imipramine antidepressant activity by thyroid hormone. Am J Psychiatry. 1969;126(4):457-469.
7. Bauer MS, Whybrow PC, Winokur A. Rapid cycling bipolar affective disorder. I. Association with grade I hypothyroidism. Arch Gen Psychiatry. 1990;47(5):427-432.
8. Bauer M, Whybrow PC. Thyroid hormone, neural tissue and mood modulation. World J Biol Psychiatry. 2001;2(2):59-69.
9. Larsen PR. The thyroid gland. In: Williams RH, Foster DW, Kronenberg HM, Larsen PR, Wilson JD, eds. Williams Textbook of Endocrinology. 9th ed. Philadelphia, PA: Saunders; 1998:389-515.
10. Leonhard JL, Kohrle J. Intracellular pathways of iodothyronine metabolism. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:136-171.
11. St Germain DL, Galton VA. The deiodinase family of selenoproteins. Thyroid. 1997;7(4):655-668.
12. Kohrle J. Thyroid hormone metabolism and action in the brain and pituitary. Acta Med Austriaca. 2000;27(1):1-7.
13. Brent GA. The molecular basis of thyroid hormone action. N Engl J Med. 1994;331(13):847-853.
14. Porterfield SP, Hendrich CE. The role of thyroid hormones in prenatal and neonatal neurological development-current perspectives. Endocr Rev. 1993;14(1):94-106.
15. Bernal J, Nunez J. Thyroid hormones and brain development. Eur J Endocrinol. 1995;133(4):390-398.
16. Arii J, Tanabe Y, Makino M, Sato H, Kohno Y. Children with irreversible brain damage associated with hypothyroidism and multiple intracranial calcifications. J Child Neurol. 2002;17(4):309-313.
17. Dussault JH, Ruel J. Thyroid hormones and brain development. Annu Rev Physiol. 1987;49:321-434.
18. Smallridge RC. Metabolic, physiologic, and clinical indexes of thyroid function. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:393-401.
19. Schwartz HL, Oppenheimer JH. Nuclear triiodothyronine receptor sites in brain: probable identity with hepatic receptors and regional distribution. Endocrinology. 1978;103(1):267-273.
20. Ruel J, Faure R, Dussault JH. Regional distribution of nuclear T3 receptors in rat brain and evidence for preferential localization in neurons. J Endocrinol Invest. 1985;8(4):343-348.
21. Braverman LE, Utiger RD. Introduction to thyrotoxicosis. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins: 2000:515-517.
22. Taylor JW. Depression in thyrotoxicosis. Am J Psychiatry. 1975;132(5):552-553.
23. Peake RL. Recurrent apathetic hyperthyroidism. Arch Intern Med. 1981;141(2):258-260.
24. Kathol RG, Delahunt JW. The relationship of anxiety and depression to symptoms of hyperthyroidism using operational criteria. Gen Hosp Psychiatry. 1986;8(1):23-28.
25. Trzepacz PT, McCue M, Klein I, Levey GS, Greenhouse J. A psychiatric and neuropsychological study of patients with untreated Graves' disease. Gen Hosp Psychiatry. 1988;10(1):49-55.
26. Lidz T, Whitehorn JC. Psychiatric problems in a thyroid clinic. JAMA. 1949;139:698-701.
27. Bursten B. Psychoses associated with thyrotoxicosis. Arch Gen Psychiatry. 1961;4:267-273.
28. Checkley SA. Thyrotoxicosis and the course of manic-depressive illness. Br J Psychiatry. 1978;133:219-223.
29. Hasan MK, Mooney RP. Mania and thyrotoxicosis. J Fam Pract. 1981;13(1):113,117-118.
30. Reus VI, Gold P, Post R. Lithium-induced thyrotoxicosis. Am J Psychiatry. 1979;136(5):724-725.
31. Braverman LE, Utiger RD. Introduction to hypothyroidism. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:719-720.
32. Whybrow PC, Prange AJ Jr, Treadway CR. Mental changes accompanying thyroid gland dysfunction. A reappraisal using objective psychological measurement. Arch Gen Psychiatry. 1969;20(1):48-63.
33. Whybrow PC, Bauer M. Behavioral and psychiatric aspects of hypothyroidism. In: Braverman LE, Utiger RD, eds. Werner & Ingbar's The Thyroid: A Fundamental and Clinical Text. 8th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2000:837-842.
34. Bauer M, London ED, Silverman DH, Rasgon N, Kirchheiner J, Whybrow PC. Thyroid, brain and mood modulation in affective disorder: insights from molecular research and functional brain imaging. Pharmacopsychiatry. 2003;36(suppl 3):S215-S221.
35. Wenzel KW, Meinhold H, Raffenberg M, Adlkofer F, Schleusener H. Classification of hypothyroidism in evaluating patients after radioiodine therapy by serum cholesterol, T3-uptake. Total T4, FT4-index, total T3, basal TSH and TRH-test. Eur J Clin Invest. 1974;4(2):141-148.
36. Gold MS, Pottash AL, Extein I. Hypothyroidism and depression. Evidence from complete thyroid function evaluation. JAMA. 1981;245(19):1919-1922.
37. Haggerty JJ Jr, Prange AJ Jr. Borderline hypothyroidism and depression. Annu Rev Med. 1995;46:37-46.
38. Haggerty JJ Jr, Stern RA, Mason GA, Beckwith J, Morey CE, Prange AJ Jr. Subclinical hypothyroidism: a modifiable risk factor for depression? Am J Psychiatry. 1993;150(3):508-510.
39. Joffe RT, Marriott M. Thyroid hormone levels and recurrence of major depression. Am J Psychiatry. 2000;157(10):1689-1691.
40. Loosen PT, Prange AJ Jr. Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Am J Psychiatry. 1982;139(4):405-416.
41. Bauer MS, Whybrow PC. Thyroid hormones and the central nervous system in affective illness: interactions that may have clinical significance. Integr Psychiatry. 1988;6:75-100.
42. Baumgartner A, Graf KJ, Kurten I, Meinhold H. The hypothalamic-pituitary- thyroid axis in psychiatric patients and healthy subjects: Parts 1-4. Psychiatry Res. 1988;24(3):271-332.
43. Loosen PT. The TRH-induced TSH response in psychiatric patients: a possible neuroendocrine marker. Psychoneuroendocrinology. 1985;10(3):237-260.
44. Mason GA, Garbutt JC, Prange AJ. Thyrotropin-releasing hormone. In: Bloom, FE, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. New York, NY: Raven Press; 1995:493-503.
45. Banki CM, Bissette G, Arato M, Nemeroff CB. Elevation of immunoreactive CSF TRH in depressed patients. Am J Psychiatry. 1988;145(12):1526-1531.
46. Frye MA, Denicoff KD, Bryan AL, et al. Association between lower serum free T4 and greater mood instability and depression in lithium-maintained bipolar patients. Am J Psychiatry. 1999;156(12):1909-1914.
47. Cole DP, Thase ME, Mallinger AG, et al. Slower treatment response in bipolar depression predicted by lower pretreatment thyroid function. Am J Psychiatry. 2002;159(1):116-121.
48. Whybrow PC. Sex differences in thyroid axis function: relevance to affective disorder and its treatment. Depression. 1995;3:33-42.
49. Bartalena L, Pellegrini L, Meschi M, et al. Evaluation of thyroid function in patients with rapid-cycling and non-rapid-cycling bipolar disorder. Psychiatry Res. 1990;34(1):13-17.
50. Kusalic M. Grade II and grade III hypothyroidism in rapid-cycling bipolar patients. Neuropsychobiology. 1992;25(4):177-181.
51. Oomen HA, Schipperijn AJ, Drexhage HA. The prevalence of affective disorder and in particular of a rapid cycling of bipolar disorder in patients with abnormal thyroid function tests. Clin Endocrinol (Oxf). 1996;45(2):215-223.
52. Cowdry RW, Wehr TA, Zis AP, Goodwin FK. Thyroid abnormalities associated with rapid-cycling bipolar illness. Arch Gen Psychiatry. 1983;40(4):414-420.
53. Gyulai L, Bauer M, Bauer MS, Garcia-Espana F, Cnaan A, Whybrow PC. Thyroid hypofunction in patients with rapid-cycling bipolar disorder after lithium challenge. Biol Psychiatry. 2003;53(10):899-905.
54. Bauer MS, Whybrow PC. Rapid cycling bipolar affective disorder. II. Treatment of refractory rapid cycling with high-dose levothyroxine: a preliminary study. Arch Gen Psychiatry. 1990;47(5):435-440.
55. Baumgartner A, Bauer M, Hellweg R. Treatment of intractable non-rapid cycling bipolar affective disorder with high-dose thyroxine: an open clinical trial. Neuropsychopharmacology. 1994;10(3):183-189.
56. Bauer M, Berghofer A, Bschor T, et al. Supraphysiological doses of L-thyroxine in the maintenance treatment of prophylaxis-resistant affective disorders. Neuropsychopharmacology. 2002;27(4):620-628.
57. Mariotti S, Chiovato L, Vitti P, et al. Recent advances in the understanding of humoral and cellular mechanisms implicated in thyroid autoimmune disorders. Clin Immunol Immunopathol. 1989;50(1 pt 2):S73-S84.
58. Vitti P, Mariotti S, Marcocci C, et al. Thyroid autoimmunity and thyroid autonomy. Acta Med Austriaca. 1990;17(suppl 1):90-92.
59. Gupta MK. Thyrotropin receptor antibodies: advances and importance of detection techniques in thyroid diseases. Clin Biochem. 1992;25(3):193-199.
60. Haggerty JJ Jr, Silva SG, Marquardt M, et al. Prevalence of antithyroid antibodies in mood disorders. Depress Anxiety. 1997;5(2):91-96.
61. Haggerty JJ Jr, Evans DL, Golden RN, Pedersen CA, Simon JS, Nemeroff CB. The presence of antithyroid antibodies in patients with affective and nonaffective psychiatric disorders. Biol Psychiatry. 1990;27(1):51-60.
62. Leroy MC, Villeneuve A, Lajeunesse C. Lithium, thyroid function and antithyroid antibodies. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12(4):483-490.
63. Lazarus JH, John R, Bennie EH, Chalmers RJ, Crockett G. Lithium therapy and thyroid function: a long-term study. Psychol Med. 1981;11(1):85-92.
64. Kupka RW, Nolen WA, Post RM, et al. High rate of autoimmune thyroiditis in bipolar disorder: lack of association with lithium exposure. Biol Psychiatry. 2002;51(4):305-311.
65. Sullivan GM, Hatterer JA, Herbert J, et al. Low levels of transthyretin in the CSF of depressed patients. Am J Psychiatry. 1999;156(5):710-715.
66. Baumgartner A. Thyroxine and the treatment of affective disorders: an overview of the results of basic and clinical research. Int J Neuropsychopharmacol. 2003;3:149-165.
67. Bauer M, Whybrow PC. Thyroid hormone and brain behavior. In: Pfaff DW, Arnold AP, Etgen AM, Fahrbach SE, Rubin RT, eds. Hormones, Brain and Behavior. San Diego, CA: Academic Press; 2002:239-264.
68. Baumgartner A, Volz HP, Campos-Barros A, Stieglitz RD, Mansmann U, Mackert A. Serum concentrations of thyroid hormones in patients with nonseasonal affective disorders during treatment with bright and dim light. Biol Psychiatry. 1996;40(9):899-907.
69. Joffe R, Segal Z, Singer W. Change in thyroid hormone levels following response to cognitive therapy for major depression. Am J Psychiatry. 1996;153(3):411-413.
70. George MS, Wassermann EM, Williams WA, et al. Changes in mood and hormone levels after rapid-rate transcranial magnetic stimulation (rTMS) of the prefrontal cortex. J Neuropsychiatry Clin Neurosci. 1996;8(2):172-180.
71. Marangell LB, Ketter TA, George MS, et al. Inverse relationship of peripheral thyrotropin-stimulating hormone levels to brain activity in mood disorders. Am J Psychiatry. 1997;154(2):224-230.
72. Bauer M, Heinz A, Whybrow PC. Thyroid hormones, serotonin and mood: of synergy and significance in the adult brain. Mol Psychiatry. 2002;7(2):140-156.
73. Altshuler LL, Bauer M, Frye MA, et al. Does thyroid supplementation accelerate tricyclic antidepressant response? A review and meta-analysis of the literature. Am J Psychiatry. 2001;158(10):1617-1622.
74. Coppen A, Whybrow PC, Noguera R, Maggs R, Prange AJ Jr. The comparative antidepressant value of L-tryptophan and imipramine with and without attempted potentiation by liothyronine. Arch Gen Psychiatry. 1972;26(3):234-241.
75. Wheatley D. Potentiation of amitriptyline by thyroid hormone. Arch Gen Psychiatry. 1972;26(3):229-233.
76. Aronson R, Offman HJ, Joffe RT, Naylor CD. Triiodothyronine augmentation in the treatment of refractory depression. A meta-analysis. Arch Gen Psychiatry. 1996;53(9):842-848.
77. Bauer M, Hellweg R, Graf KJ, Baumgartner A. Treatment of refractory depression with high-dose thyroxine. Neuropsychopharmacology. 1998;18(6):444-455.
78. Pfeiffer H, Scherer J, Albus M. L-thyroxin-hochdosierung bei therapieresistenter depression: fallauswertung und katamnese als qualitätskontrolle. Nervenarzt. 2004;75(3):242-248.
79. Hurowitz GI, Liebowitz MR. Antidepressant-induced rapid cycling: six case reports. J Clin Psychopharmacol. 1993;13(1):52-56.
80. Afflelou S, Auriacombe M, Cazenave M, Chartres JP, Tignol J. Administration of high dose levothyroxine in treatment of rapid cycling bipolar disorders. Review of the literature and initial therapeutic application apropos of 6 cases [in German]. Encephale. 1997;23(3):209-217.
81. Bauer M, Priebe S, Berghofer A, Bschor T, Kiesslinger U, Whybrow PC. Subjective response to and tolerability of long-term supraphysiological doses of levothyroxine in refractory mood disorders. J Affect Disord. 2001;64(1):35-42.
82. Jackson IM. Does thyroid hormone have a role as adjunctive therapy in depression? Thyroid. 1996;6(1):63-67.
83. Joffe RT, Sokolov ST. Thyroid hormone treatment of primary unipolar depression: a review. Int J Neuropsychopharmacol. 2000;3(2):143-147.
84. Agid O, Lerer B. Algorithm-based treatment of major depression in an outpatient clinic: clinical correlates of response to a specific serotonin reuptake inhibitor and to triiodothyronine augmentation. Int J Neuropsychopharmacol. 2003;6(1):41-49.
85. Wilson IC, Prange AJ Jr, Lara P. L-triiodthyronine alone and with imipramine in the treatment of depressed women. In: Prange AJ Jr, ed. The Thyroid Axis, Drugs, and Behavior. New York, NY: Raven Press; 1974:49-62.
86. Okuno Y, Nakayasu N. Thyroid function and therapeutic efficacy of thyroxine in depression. Jpn J Psychiatry Neurol. 1988;42(4):763-770.
87. Marangell LB, George MS, Callahan AM, et al. Effects of intrathecal thyrotropin-releasing hormone (protirelin) in refractory depressed patients. Arch Gen Psychiatry. 1997;54(3):214-222.
88. Callahan AM, Frye MA, Marangell LB, et al. Comparative antidepressant effects of intravenous and intrathecal thyrotropin-releasing hormone: confounding effects of tolerance and implications for therapeutics. Biol Psychiatry. 1997;41(3):264-272.
89. Prange AJ Jr, Wilson IC, Knox A, McClane TK, Lipton MA. Enhancement of imipramine by thyroid stimulating hormone: clinical and theoretical implications. Am J Psychiatry. 1970;127(2):191-199.